Neurovirulent factor ICP34.5 uniquely expressed in the herpes simplex virus type 1 Delta gamma 1 34.5 mutant 1716
- PMID: 18300073
- DOI: 10.1080/13550280701769999
Neurovirulent factor ICP34.5 uniquely expressed in the herpes simplex virus type 1 Delta gamma 1 34.5 mutant 1716
Abstract
The herpes simplex virus type 1 (HSV-1) diploid gene gamma(1)34.5 encodes a neurovirulent factor, infected cell protein 34.5 (ICP34.5). The promoter to gamma(1)34.5 is located within the HSV-1 genome where there are repeated sequences. This region of the genome also contains important overlapping transcripts involved with the virus's ability to establish lytic and latent infections and reactivation. These transcripts include the latency-associated transcripts and regulator proteins ICP0 and ICP4. This study aimed to separate ICP34.5 from these overlapping transcripts and test if its expression from a single gene could restore wild-type HSV-1 strain 17+ virulence. To address these aims, different recombinant viruses were constructed using the Delta gamma(1)34.5 mutant 1716. Immunoblots probed with different ICP34.5 antisera demonstrated that one of the newly generated recombinant viruses, 1622, overexpresses ICP34.5 relative to a panel of wild-type viruses. Interestingly, the overexpression of ICP34.5 does not yield a more virulent virus. The onset of ICP34.5 expression from 1622-infected cells in vitro matched that of 17+, and its expression restored the function of maintaining protein synthesis in human neuroblastoma cells. Replication of 1622, however, was only partially restored to 17+ levels in vivo. Additionally, plaque morphology from 1622-infected cells indicates there is an additional defect. The authors report that the mutant virus 1622 can express ICP34.5 from a single gamma(1)34.5 gene and restore most (but not all) wild-type function. These findings are discussed with respect to the use of the gamma(1)34.5 deleted mutant, 1716, in oncolytic viral vector therapies and future studies for ICP34.5.
Similar articles
-
A virus with a mutation in the ICP4-binding site in the L/ST promoter of herpes simplex virus type 1, but not a virus with a mutation in open reading frame P, exhibits cell-type-specific expression of gamma(1)34.5 transcripts and latency-associated transcripts.J Virol. 1998 May;72(5):4250-64. doi: 10.1128/JVI.72.5.4250-4264.1998. J Virol. 1998. PMID: 9557715 Free PMC article.
-
The region of the herpes simplex virus type 1 LAT gene that is colinear with the ICP34.5 gene is not involved in spontaneous reactivation.J Virol. 1996 Jan;70(1):282-91. doi: 10.1128/JVI.70.1.282-291.1996. J Virol. 1996. PMID: 8523537 Free PMC article.
-
Strain-dependent structural variants of herpes simplex virus type 1 ICP34.5 determine viral plaque size, efficiency of glycoprotein processing, and viral release and neuroinvasive disease potential.J Virol. 2003 Mar;77(6):3409-17. doi: 10.1128/jvi.77.6.3409-3417.2003. J Virol. 2003. PMID: 12610116 Free PMC article.
-
Interplay between Autophagy and Herpes Simplex Virus Type 1: ICP34.5, One of the Main Actors.Int J Mol Sci. 2022 Nov 7;23(21):13643. doi: 10.3390/ijms232113643. Int J Mol Sci. 2022. PMID: 36362429 Free PMC article. Review.
-
Herpes simplex virus type 1 persists in the aged brain through hypothetical expression of accessory genes.J Neurovirol. 2010 May;16(3):203-7. doi: 10.3109/13550281003739040. J Neurovirol. 2010. PMID: 20450378 Review.
Cited by
-
Novel less-abundant viral microRNAs encoded by herpes simplex virus 2 latency-associated transcript and their roles in regulating ICP34.5 and ICP0 mRNAs.J Virol. 2009 Feb;83(3):1433-42. doi: 10.1128/JVI.01723-08. Epub 2008 Nov 19. J Virol. 2009. PMID: 19019961 Free PMC article.
-
Novel Therapies in Glioblastoma Treatment: Review of Glioblastoma; Current Treatment Options; and Novel Oncolytic Viral Therapies.Med Sci (Basel). 2023 Dec 23;12(1):1. doi: 10.3390/medsci12010001. Med Sci (Basel). 2023. PMID: 38249077 Free PMC article. Review.
-
Oncolytic Viruses as a Platform for the Treatment of Malignant Brain Tumors.Int J Mol Sci. 2020 Oct 9;21(20):7449. doi: 10.3390/ijms21207449. Int J Mol Sci. 2020. PMID: 33050329 Free PMC article. Review.
-
Harnessing innate immunity against glioblastoma microenvironment.Front Immunol. 2025 Jul 25;16:1648601. doi: 10.3389/fimmu.2025.1648601. eCollection 2025. Front Immunol. 2025. PMID: 40787444 Free PMC article. Review.
-
Progress of oncolytic virotherapy for neuroblastoma.Front Pediatr. 2022 Nov 18;10:1055729. doi: 10.3389/fped.2022.1055729. eCollection 2022. Front Pediatr. 2022. PMID: 36467495 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources